Oncoinvent would like to extend an invitation to a short update on the company. The presentation will be held on Friday 17. February 2023 at 09:00 AM in the company offices at Gullhaugsveien 7, Oslo, 3rd Floor. It will also be possible to attend virtually. To attend, please register with kvam@oncoinvent.com. ————————————————– Oncoinvent ønsker med … Read more
Oncoinvent AS, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, today announced strong progress with clinical trials, including patient recruitment and efficacy signals. Further updates will be provided in an upcoming investor conference call.
Oncoinvent ASA Gullhaugveien 7 0484 Oslo Norway
mansson@oncoinvent.com
Anders Månsson is a business executive with over 25 years of experience from management roles in the pharmaceutical industry, focusing on commercialisation and M&A + licensing. Mr. Månsson has held leading roles in the industry both in his native Sweden and in other European countries, and he has worked extensively with the USA and Asia as focus markets in global roles.
Mr. Månsson holds a B.Sc. degree in Business & Economics from Lund’s University in Sweden as well as an MBA from Business School Lausanne in Switzerland. He has a broad-based industrial experience, featuring both large multinational companies such as Meda, Ferring & LEO Pharma, and including leading roles in start-ups and smaller biotech companies. On top of his executive role in Oncoinvent, Mr. Månsson holds two non-executive director positions serving on the board of EQL Pharma AB as well Immetric AB, the latter being an investment company focusing on life science.